| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1374
Nuclear factor 
B (NF-B) plays a major role in the pathogenesis of human T-cell lymphotrophic virus I-associated malignancy. Proteasome inhibitors provide a rational approach to control constitutively activated NF-B in human T-cell lymphotrophic virus I-infected T cells. We report that the proteasome inhibitor PS-341 decreased NF-B DNA binding activity by preventing degradation of IB
. In our murine model of adult T-cell leukemia, PS-341 used alone did not yield prolongation of the survival of tumor-bearing mice. However, when combined with the current clinically approved drug humanized anti-Tac, therapy with PS-341 was associated with a complete remission in a proportion of treated animals, whereas only a partial response was observed in animals treated with humanized anti-Tac alone.
This article has been cited by other articles:
|
|
 |
|
  S. T. Shu, M. V.P. Nadella, W. P. Dirksen, S. A. Fernandez, N. K. Thudi, J. L. Werbeck, M. D. Lairmore, and T. J. Rosol A Novel Bioluminescent Mouse Model and Effective Therapy for Adult T-Cell Leukemia/Lymphoma Cancer Res., December 15, 2007; 67(24): 11859 - 11866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Naik and D. Piwnica-Worms Real-time imaging of beta-catenin dynamics in cells and living mice PNAS, October 30, 2007; 104(44): 17465 - 17470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zou, J. Kawada, L. Pesnicak, and J. I. Cohen Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells J. Virol., September 15, 2007; 81(18): 10029 - 10036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 PNAS, May 15, 2007; 104(20): 8444 - 8448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kashkar, A. Deggerich, J.-M. Seeger, B. Yazdanpanah, K. Wiegmann, D. Haubert, C. Pongratz, and M. Kronke NF-{kappa}B-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs Blood, May 1, 2007; 109(9): 3982 - 3988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al. The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia Cancer Res., August 15, 2006; 66(16): 8227 - 8232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25 Blood, August 1, 2006; 108(3): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Carter, D. H. Mak, W. D. Schober, M. Cabreira-Hansen, M. Beran, T. McQueen, W. Chen, and M. Andreeff Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells Blood, February 15, 2006; 107(4): 1555 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Chang and S. Miyamoto Nuclear Factor-{kappa}B Dimer Exchange Promotes a p21waf1/cip1 Superinduction Response in Human T Leukemic Cells Mol. Cancer Res., February 1, 2006; 4(2): 101 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Z. Dewan, J.-n. Uchihara, K. Terashima, M. Honda, T. Sata, M. Ito, N. Fujii, K. Uozumi, K. Tsukasaki, M. Tomonaga, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir Blood, January 15, 2006; 107(2): 716 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, et al. Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells Cancer Res., January 1, 2006; 66(1): 184 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-{kappa}B, as a strategy for chemoprevention and therapy of adult T-cell leukemia Blood, October 1, 2005; 106(7): 2462 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ohsugi, R. Horie, T. Kumasaka, A. Ishida, T. Ishida, K. Yamaguchi, T. Watanabe, K. Umezawa, and T. Urano In vivo antitumor activity of the NF-{kappa}B inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia Carcinogenesis, August 1, 2005; 26(8): 1382 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhang, M. H. Ahsan, L. Zhu, L. C. Sambucetti, A. F. Purchio, and D. B. West NF-{kappa}B and Not the MAPK Signaling Pathway Regulates GADD45{beta} Expression during Acute Inflammation J. Biol. Chem., June 3, 2005; 280(22): 21400 - 21408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Matsuoka and K.-T. Jeang Human T-Cell Leukemia Virus Type I at Age 25: A Progress Report Cancer Res., June 1, 2005; 65(11): 4467 - 4470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Orlowski, P. M. Voorhees, R. A. Garcia, M. D. Hall, F. J. Kudrik, T. Allred, A. R. Johri, P. E. Jones, A. Ivanova, H. W. Van Deventer, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood, April 15, 2005; 105(8): 3058 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Zhang, C. K. Goldman, J. Janik, and T. A. Waldmann Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody Blood, February 1, 2005; 105(3): 1231 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia Cancer Res., August 15, 2004; 64(16): 5825 - 5829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mitra-Kaushik, J. C. Harding, J. L. Hess, and L. Ratner Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants Blood, August 1, 2004; 104(3): 802 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cortes, D. Thomas, C. Koller, F. Giles, E. Estey, S. Faderl, G. Garcia-Manero, D. McConkey, G. Patel, R. Guerciolini, et al. Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias Clin. Cancer Res., May 15, 2004; 10(10): 3371 - 3376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D. J. McConkey The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts Mol. Cancer Ther., January 1, 2004; 3(1): 59 - 70. [Abstract] [Full Text]
|
|
|
|
|
|
C. Nakahara, K. Nakamura, N. Yamanaka, E. Baba, M. Wada, H. Matsunaga, H. Noshiro, M. Tanaka, T. Morisaki, and M. Katano Cyclosporin-A Enhances Docetaxel-Induced Apoptosis through Inhibition of Nuclear Factor-{kappa}B Activation in Human Gastric Carcinoma Cells Clin. Cancer Res., November 1, 2003; 9(14): 5409 - 5416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, M. Zhang, C. K. Goldman, J. V. Ravetch, and T. A. Waldmann Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H Cancer Res., October 1, 2003; 63(19): 6453 - 6457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, M. Zhang, J. V. Ravetch, C. Goldman, and T. A. Waldmann Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507 Blood, July 1, 2003; 102(1): 284 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Z. Dewan, K. Terashima, M. Taruishi, H. Hasegawa, M. Ito, Y. Tanaka, N. Mori, T. Sata, Y. Koyanagi, M. Maeda, et al. Rapid Tumor Formation of Human T-Cell Leukemia Virus Type 1-Infected Cell Lines in Novel NOD-SCID/{gamma}cnull Mice: Suppression by an Inhibitor against NF-{kappa}B J. Virol., May 1, 2003; 77(9): 5286 - 5294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hideshima, C. Mitsiades, M. Akiyama, T. Hayashi, D. Chauhan, P. Richardson, R. Schlossman, K. Podar, N. C. Munshi, N. Mitsiades, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood, February 15, 2003; 101(4): 1530 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Orlowski, T. E. Stinchcombe, B. S. Mitchell, T. C. Shea, A. S. Baldwin, S. Stahl, J. Adams, D.-L. Esseltine, P. J. Elliott, C. S. Pien, et al. Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies J. Clin. Oncol., November 15, 2002; 20(22): 4420 - 4427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. LeBlanc, L. P. Catley, T. Hideshima, S. Lentzsch, C. S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C. S. Pien, J. Adams, et al. Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model Cancer Res., September 1, 2002; 62(17): 4996 - 5000. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
